| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05630859 | Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. | PHASE1 | COMPLETED | 1,004 | — | — | Nov 28, 2022 | May 22, 2025 | Aug 7, 2025 | 23 | United States, Brazil +6 |
The solicited administration site events after vaccination include pain, redness, and swelling.
The solicited systemic events after vaccination include fever, headache, myalgia, arthralgia, fatigue. Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for measuring temperature in this study is the oral cavity.
Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in an abnormal pregnancy outcome.
An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention.
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
The solicited administration site events after vaccination include pain, redness, and swelling.
The solicited systemic events after vaccination include fever, headache, myalgia, arthralgia, fatigue. Fever is defined as temperature ≥ 38.0°C/100.4°F. The preferred location for measuring temperature in this study is the oral cavity.
Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in an abnormal pregnancy outcome.
An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention.
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. The evaluation of the endpoint will be assessed in the subsets for intensive safety monitoring.
| Arm | Type | Description |
|---|---|---|
| Phase 1:1a Low dose Group | EXPERIMENTAL | Participants randomized to the 1a Low dose Group receive 2 doses of NgG low dose investigational vaccine. |
| Phase 1:1b Placebo Group | PLACEBO_COMPARATOR | Participants randomized to the 1b Placebo Group receive 2 doses of placebo. |
| Phase 1: 2a Medium dose Group | EXPERIMENTAL | Participants randomized to the 2a Medium dose Group receive 2 doses of NgG medium dose investigational vaccine. |
| Phase 1: 2b Placebo Group | PLACEBO_COMPARATOR | Participants randomized to the 2b Placebo Group receive 2 doses of placebo. |
| Phase 1: 3a High dose Group | EXPERIMENTAL | Participants randomized to the 3a High dose Group receive 2 doses of NgG high dose investigational vaccine. |
| Phase 1: 3b Placebo Group | PLACEBO_COMPARATOR | Participants randomized to the 3b Placebo Group receive 2 doses of placebo. |
| Phase 2: 4a HTD Group | EXPERIMENTAL | Participants randomized to the 4a highest tolerated dose (HTD) Group receive 2 doses of NgG highest tolerated dose selected from Phase 1. |
| Phase 2: 4b dose below HTD Group | EXPERIMENTAL | Participants randomized to the 4b dose below HTD Group receive 2 doses of NgG dose below the highest tolerated dose selected from Phase 1. |
| Phase 2: 4c Placebo Group | PLACEBO_COMPARATOR | Participants randomized to the 4c Placebo Group receive 2 doses of placebo. |
| Name | Type | Description |
|---|---|---|
| NgG low dose investigational vaccine | BIOLOGICAL | Two doses of NgG low dose investigational vaccine, administered intramuscularly. |
| NgG medium dose investigational vaccine | BIOLOGICAL | Two doses of NgG medium dose investigational vaccine, administered intramuscularly. |
| NgG high dose investigational vaccine | BIOLOGICAL | Two doses of NgG high dose investigational vaccine, administered intramuscularly. |
| Placebo | BIOLOGICAL | Two doses of placebo, administered intramuscularly. |
| NgG HTD investigational vaccine | BIOLOGICAL | Two doses of NgG HTD investigational vaccine, administered intramuscularly. |
| NgG below HTD investigational vaccine | BIOLOGICAL | Two doses of NgG below HTD investigational vaccine, administered intramuscularly. |
Inclusion Criteria: Inclusion criteria for the dose-escalation safety lead-in part * Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed/thumb printed informed consent obtained from the participant prior to perfor...